Fireman B.V. (IFRX)

$IFRX Happy Thanksgiving, everyone! Remember the most important things in life are family, friends and good health. These values are the true meaning of wealth. Our time with Inflarx will come.

$IFRX No partner, No party !!

$IFRX I seem to recall that comment as well —“something about data integrity and proper wind down so the data are preserved”. Implying some value. yet missing 100% closure endpoint.

$IFRX Everyone ready for a hit of the obvious… People heal at different rates. Yes, let it be known that there’s nothing magical about 6 months to perfection. The more one’s comorbidities, or as I like to think of it – the more one’s chronic inflammation – longer is their PG ulcer healing. “While further efforts are needed to establish standardized methods for detecting and addressing underlying conditions that might affect healing outcomes in PG, our results emphasize the need for implementing proactive comorbidity management along with therapeutic interventions in improving treatment outcomes.” CD11b expression measures anyone? Vilo for longer, continuing the sustained trend towards 100% ulcer closure, there’s some practicality to be thinking about. https://pmc.ncbi.nlm.nih.gov/articles/PMC12640798/

$IFRX Dear Hospitals: Gohibic helps ppl w ARDS Love, The Green Monkeys Breaking: https://www.medrxiv.org/content/10.1101/2025.11.21.25340167v2

$IFRX just trying some luck here in 2025.

$IFRX I meant 10000 shares. 1.19

$IFRX Happy Thanksgiving to all fellow IFRX investors! This year has felt like owning a tiny biotech lottery ticket that insists on giving us plot twists instead of straight lines. Grateful for the patience, the dark-humor memes on red days, and the stubborn hope that science and catalysts eventually catch up to the share price. Here’s to good data, kind regulators, surprise green candles, and a holiday table as full as our conviction in the year ahead.

$IFRX grabbed 1000 for fun.

$IFRX interesting 🔋 https://www.dermatologytimes.com/view/inf904-demonstrates-biologic-like-efficacy-in-hs-and-csu

$IFRX https://seekingalpha.com/article/4845899-inflarx-stock-gohibic-niche-inf904-underwhelms-cash-burn-accelerates-rating-downgrade

$IFRX Mrk possible partner ...yes...they have a current relationship

$IFRX new short interest released. Its grew 57% up to 2.15m, highest in years, maybe ever (1.35m 2 weeks ago). New Short is —as of 11/15, so this included all the crazy post / pre maker shenanigans. This is a good sign as volume normalizes. We know eventually someone has to buy back. Bases on yesterday’s volume it would take 2.62 days to cover and represents 3.77% of float (non dilutive) Anything that’s up 40-80% pre post will draw in some shorts. Liquidity allows more confidence to easily cover- but lack there of cld cause volatility. APR to short normalized through yesterday but seeing slight increase today. Same w available to short—-normal w less available.

$IFRX you are closer than ever, keep the faith, best in class..nothing but good ahead!! 🤮🤮🤮

$IFRX in the season of Thanksgiving - many thanks to all for sharing this time together, let's not waste any moment, fretting about things out of our control - pretty much everything! Wir danken allen!¡Damos gracias a todos! MEGA

$IFRX Data is KING! Know what you own.

$IFRX Big Pharma has probably seen the data and it's not good for them. Or Niels, as usual, wants to dilute the activists and is waiting for the right moment. Time is running out; no partner, no party.

$IFRX Niels seems like a desperate and misunderstood man, but he brought this trouble on himself and has no one to blame. He's driving the company into bankruptcy and Chapter 11, and the money is running out.

$IFRX don't give up, don't you ever give up 🤑🤑🤑

$IFRX Based on InflaRx’s (IFRX) recent positive Phase 2a topline data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), announced on November 10, 2025, the company is in a strong position to attract a partner. This oral C5aR inhibitor showed rapid onset and efficacy superior to existing treatments in HS, with a clean safety profile. The data echoes the preclinical asset that prompted Biogen’s $1.1 billion acquisition of Vanqua Bio in October 2025 for a similar mechanism. InflaRx has been actively seeking commercial partners for its assets, as noted in their Q2 2025 earnings, particularly for GOHIBIC (vilobelimab) distribution outside the U.S. and for advancing their pipeline. With cash runway into 2027 and a market cap under $300 million post-data surge, the setup is attractive for big pharma—especially given the HS market’s growth (projected to exceed $5 billion by 2030) and unmet needs in CSU. Biotech patterns show partnerships often materialize 1-4 months after compelling Phase 2 data, as seen with recent deals like Novo Nordisk/Septerna ($2.2 billion for oral GLP-1s in May 2025) or Biogen/Vanqua. Analyst sentiment and investor chatter on platforms like X highlight IFRX as undervalued and a “takeout candidate,” with speculation of imminent interest from majors like Biogen or others in inflammation/immunology. My prediction: InflaRx lands a partnership (likely a licensing or co-development deal for INF904) by mid-Q1 2026 (February-March). This is speculative but grounded in the fresh data catalyst, low valuation, and active partnering pursuit. Risks include data scrutiny or market conditions delaying it to Q2.

$IFRX at these price levels, partnership conditions will be weak for Inflarx and they will be forced to accept peanuts